D. E. Shaw & Co., Inc. Vertex Pharmaceuticals Inc Transaction History
D. E. Shaw & Co., Inc.
- $100 Billion
- Q1 2025
A detailed history of D. E. Shaw & Co., Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 71,933 shares of VRTX stock, worth $32.5 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
71,933
Previous 265,684
72.93%
Holding current value
$32.5 Million
Previous $107 Million
67.4%
% of portfolio
0.03%
Previous 0.09%
Shares
31 transactions
Others Institutions Holding VRTX
# of Institutions
1,833Shares Held
233MCall Options Held
1.38MPut Options Held
1.08M-
Capital World Investors Los Angeles, CA28.5MShares$12.9 Billion2.34% of portfolio
-
Vanguard Group Inc Valley Forge, PA23.5MShares$10.6 Billion0.21% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$9.62 Billion0.23% of portfolio
-
Capital Research Global Investors Los Angeles, CA14.5MShares$6.56 Billion1.6% of portfolio
-
State Street Corp Boston, MA11.8MShares$5.32 Billion0.24% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $116B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...